1. United States of America Stocks

  2. •

    Consumer Defensive

  3. •

    Tobacco
Nicodrops, Inc.

Nicodrops, Inc.

NCDP
Nicodrops, Inc.US flagOther OTC
0.00
USD
- -
- -
3,696.00Market Cap
No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

APIChatGPT
CEO
James A. Bowen
Sector
Consumer Defensive
Industry
Tobacco
Address
PO Box 371711 San Diego IL United States of America 92137
IPO Date
Dec 28, 2022
Website
nicodrops.com
Similar Companies
PT Hanjaya Mandala Sampoerna Tbk (HMSP.JK)
British American Tobacco p.l.c. (BTI)
Vector Group Ltd. (VGR)
Nicoccino Holding AB (publ) (NICO.ST)
Pyxus International, Inc. (PYYX)
Karelia Tobacco Company Inc. (KARE.AT)
Business
Nicodrops, Inc. (NCDP) develops and markets drug-free, non-nicotine smoking cessation alternatives consisting of herbal dietary supplements in lozenge form in the United States; its core product is a mint-flavored cough drop featuring natural herbal ingredients such as lobelia, echinacea and licorice root that help alleviate the stress and cravings associated with nicotine withdrawal. The company, founded in 1993 and headquartered in San Diego, California, with certain operations listed in Las Vegas, Nevada, operates within the household and personal products industry, targeting adult smokers seeking natural cessation aids through over-the-counter distribution channels. No major acquisitions, funding rounds, partnerships or product launches have been reported in the last two years, with the firm maintaining its focus on its established lozenge portfolio amid stagnant market activity on the OTC Markets.